Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| New York Genome Center | RCV004555155 | SCV005044068 | likely pathogenic | Glaucoma 3, primary congenital, E | 2023-02-23 | criteria provided, single submitter | clinical testing | The c.3200+1G>A variant in TEK has not previously been reported in the literature or public variant repositories (ClinVar and LOVD), and is absent from population databases (gnomAD v2.1.1 and v3.1.2, TOPMed Freeze 8), suggesting it is not a common benign variant in the populations represented in those databases.The c.3200+1G>A variant in TEK is located in the canonical splice donor site of exon 21 of this 23-exon gene, and is predicted to result in loss of native splice donor site and introduce a cryptic splice donor site 3 bp upstream of the variant (splice AI= 0.94 (DL); 0.37 (DG)), which might result in disruption of open reading frame and incorporation of premature stop codon that is 100 bp upstream of the penultimate exon-intron junction, hence lead to loss-of-function via nonsense mediated decay; however, there are no functional studies to support or refute these predictions. Another downstream canonical splice site variant (c.3300+2delT) was reported in an individual with congenital onset bilateral glaucoma (PMID: 27270174] and downstream loss-of function variants identified in individuals with early onset glaucoma have been deposited in ClinVar [ClinVar IDs= 1687360, 1333465]. Based on available evidence this de novo c.3200+1G>A variant identified in TEK is classified as Likely Pathogenic. |